Home  /  Resource Library  /  CLL2-GIVE, A PROSPECTIVE, OPEN-LABEL, MULTICENTER PHASE-II TRIAL OF OBINUTUZUMAB (GA101, G), IBRUTINIB (I), PLUS VENETOCLAX (VE) IN UNTREATED PATIENTS WITH CLL WITH 17P DELETION / TP53 MUTATION

CLL2-GIVE, A PROSPECTIVE, OPEN-LABEL, MULTICENTER PHASE-II TRIAL OF OBINUTUZUMAB (GA101, G), IBRUTINIB (I), PLUS VENETOCLAX (VE) IN UNTREATED PATIENTS WITH CLL WITH 17P DELETION / TP53 MUTATION

EHA 2020: Results of a phase II study examining the combination of obinutuzumab, ibrutinib and venetoclax for first line treatment of chronic lymphocytic leukemia.